RSS-Feed abonnieren
DOI: 10.1055/s-0038-1650248
Disseminated Intravascular Coagulation Is a Frequent Complication of Systemic Inflammatory Response Syndrome
Publikationsverlauf
Received: 20. April 1995
Accepted after resubmission24. Oktober 1995
Publikationsdatum:
26. Juli 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/199602/lookinside/thumbnails/10-1055-s-0038-1650248-1.jpg)
Summary
To evaluate the role of disseminated intravascular coagulation (DIC) and to determine the influence of antithrombin, protein C, and plasminogen activator inhibitor 1 on multiple organ dysfunction syndrome (MODS) and outcome in patients with systemic inflammatory response syndrome (SIRS), we made a prospective cohort study. The study subjects consisted of thirty-five patients who exhibited two or more of the conditions of SIRS for more than three consecutive days. They were classified into subgroups of survivors (n = 13) and nonsurvivors (n = 22). The global coagulation and fibrinolytic markers, antithrombin, protein C, and plasminogen activator inhibitor 1 were measured on the day of the diagnosis of SIRS, and also on the 1st, 3rd, and 5th days. The results of these measurements, demographic data, criteria of severity, incidence of MODS were compared between the subgroups. For prediction of patient’s death, a receiver operating characteristic (ROC) curve analysis was made. DIC was frequently associated with SIRS patients (29/35, 82.9%). A significant decrease in the DIC score was found in the survivors (p = 0.0001). None of them suffered from DIC on the 5th day. In the nonsurvivors, low levels of protein C and antithrombin and markedly high values of plasminogen activator inhibitor 1 continued up to the 5th day, no improvement of the DIC was observed during the study period and the number of the dysfunctioning organs were significantly higher than in the survivors. Plasminogen activator inhibitor 1 on the 5th day had prognostic value for the prediction of death on the SIRS patients. In conclusion, DIC occurs commonly in patients with SIRS and may be the main determinant for the outcome of these patients. Changes in antithrombin, protein C, and plasminogen activator inhibitor 1 are one of the aggravating factors of MODS. Furthermore, plasminogen activator inhibitor 1 is a good predictor of death in these patients.
-
References
- 1 Marder VJ, Feinstein DI, Francis CW, Colman RW. Consumptive thrombo-hemorrhagic disorders. In: Hemostasis and Thrombosis. Basic principles and clinical practice, 3rd ed Colman RW, Hirsch J, Marder VJ, Salzman EW. eds Philadelphia: Lippincott; 1994: 1023-1063
- 2 Levi M, ten Cate H, van der Poll T, van Deventer SGH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270: 975-979
- 3 Gando S, Tedo I, Kubota M. Posttrauma coagulation and fibrinolysis. Crit Care Med 1992; 20: 594-600
- 4 Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101: 816-823
- 5 Bone RC. Modulators of coagulation. A critical appraisal of their role in sepsis. Arch Intern Med 1992; 152: 1381-1389
- 6 Moalli R, Doyle JM, Tahhan HR, Hasan FM, Braman SS, Saldeen T. Fibrinolysis in critically ill patients. Am Rev Respir Dis 1989; 140: 287-293
- 7 American College of Chest Physicians/Society of Critical Care Medicine consensus conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992 20. 864-874
- 8 Scientific and Standardization Committee Communications.]. Nomenclature of quantities and units in thrombosis and haemostasis (Recommendation 1993). Thromb Haemost 1994 71. 375-394
- 9 Civil ID, Scwab CW. The abbreviated injury scale, 1985; revision: A condensed chart for clinical use. J Trauma 1988; 28: 87-90
- 10 Knaus WA, Draper EA, Wanger D, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818-829
- 11 Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988; 138: 720-723
- 12 Deitch EA. Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg 1992; 216: 117-134
- 13 Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic curve. Radiology 1982; 143:=: 29-36
- 14 Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-843
- 15 Andersson TR, Berner NS, Larsen ML, Odegaad OR, Abildgaard U. Plasma heparin cofactor II, protein C, and antithrombin in elective surgery. Acta ChirScand 1987; 153: 291-296
- 16 Francis RB, Seyfert U. Tissue plasminogen activator antigen and activity in disseminated intravascular coagulation: Clinicopathologic correlations. J Lab Clin Med 1987; 110: 541-547
- 17 Hesselvik JF, Blomback M, Brodin B, Mailer R. Coagulation, fibrinolysis, and kallikrein system in sepsis: Relation to outcome. Crit Care Med 1989; 17: 724-733
- 18 Albert J, Blomqvist H, Gardlund B, Jakobsson J, Svensson J, Blombäck M. Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiol Scand 1992; 36: 745-752
- 19 Kruithof EKO, Guidinchet A, Bachmann F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemost 1988; 59: 7-12
- 20 Pralong G, Calandra T, Glauser MP, Schellekens J, Verhoef J, Backmann F, Kruithof EKO. Plasminogen activator inhibitor-1: A new prognostic marker in septic shock. Thromb Haemost 1989; 61: 459-462
- 21 Hellgren M, Egberg N, Eklund J. Blood coagulation and fibrinolytic factors and their inhibitors in criticially ill patients. Intensive Care Med 1984; 10: 23-28
- 22 Bredbacka S, Blombäck M, Wiman B, Pelzer H. Laboratory methods for detecting disseminated intravascular coagulation (DIC): new aspects. Acta Anaesthesiol Scand 1993; 37: 125-130